TY - JOUR
T1 - Gastrointestinal stromal tumors
T2 - What do we know now?
AU - Corless, Christopher L.
N1 - Funding Information:
CLC has received honoraria, consulting fees, and research support from Novartis and Pfizer. CLC has also received a consulting fee from Bayer.
Funding Information:
We thank all the members, past and present, of the Corless and Heinrich laboratories at the Oregon Health and Science University for their continuing efforts on GIST research. Some of the works referenced in this article were supported by generous donations from the GIST Cancer Research Fund and the BP Lester Foundation, and by grant support from the LifeRaft Group.
PY - 2014/1
Y1 - 2014/1
N2 - Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the GI tract, arising from the interstitial cells of Cajal, primarily in the stomach and small intestine. They manifest a wide range of morphologies, from spindle cell to epithelioid, but are immunopositive for KIT (CD117) and/or DOG1 in essentially all cases. Although most tumors are localized at presentation, up to half will recur in the abdomen or spread to the liver. The growth of most GISTs is driven by oncogenic mutations in either of two receptor tyrosine kinases: KIT (75% of cases) or PDGFRA (10%). Treatment with tyrosine kinase inhibitors (TKIs) such as imatinib, sunitinib, and regorafenib is effective in controlling unresectable disease; however, drug resistance caused by secondary KIT or PDGFRA mutations eventually develops in 90% of cases. Adjuvant therapy with imatinib is commonly used to reduce the likelihood of disease recurrence after primary surgery, and for this reason assessing the prognosis of newly resected tumors is one of the most important roles for pathologists. Approximately 15% of GISTs are negative for mutations in KIT and PDGFRA. Recent studies of these so-called wild-type GISTs have uncovered a number of other oncogenic drivers, including mutations in neurofibromatosis type I, RAS genes, BRAF, and subunits of the succinate dehydrogenase complex. Routine genotyping is strongly recommended for optimal management of GISTs, as the type and dose of TKI used for treatment is dependent on the mutation identified.
AB - Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the GI tract, arising from the interstitial cells of Cajal, primarily in the stomach and small intestine. They manifest a wide range of morphologies, from spindle cell to epithelioid, but are immunopositive for KIT (CD117) and/or DOG1 in essentially all cases. Although most tumors are localized at presentation, up to half will recur in the abdomen or spread to the liver. The growth of most GISTs is driven by oncogenic mutations in either of two receptor tyrosine kinases: KIT (75% of cases) or PDGFRA (10%). Treatment with tyrosine kinase inhibitors (TKIs) such as imatinib, sunitinib, and regorafenib is effective in controlling unresectable disease; however, drug resistance caused by secondary KIT or PDGFRA mutations eventually develops in 90% of cases. Adjuvant therapy with imatinib is commonly used to reduce the likelihood of disease recurrence after primary surgery, and for this reason assessing the prognosis of newly resected tumors is one of the most important roles for pathologists. Approximately 15% of GISTs are negative for mutations in KIT and PDGFRA. Recent studies of these so-called wild-type GISTs have uncovered a number of other oncogenic drivers, including mutations in neurofibromatosis type I, RAS genes, BRAF, and subunits of the succinate dehydrogenase complex. Routine genotyping is strongly recommended for optimal management of GISTs, as the type and dose of TKI used for treatment is dependent on the mutation identified.
KW - GIST
KW - KIT
KW - PDGFRA
UR - http://www.scopus.com/inward/record.url?scp=84891695832&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84891695832&partnerID=8YFLogxK
U2 - 10.1038/modpathol.2013.173
DO - 10.1038/modpathol.2013.173
M3 - Article
C2 - 24384849
AN - SCOPUS:84891695832
SN - 0893-3952
VL - 27
SP - S1-S16
JO - Modern Pathology
JF - Modern Pathology
IS - SUPPL. 1
ER -